Futura Medical Share Discussion Threads

[broomrigg] 05/12/2022 16:32

Another BLUE day :-)

[lbo] 05/12/2022 10:51

And how does a company expect to enforce a patent on something that was clearly already described in research literature!?



‘The Company has conducted initial literature and in vitro based research that has shown the cooling from the evaporation of these specific combinations of solvents’



There is a risk that some claims will either be challenged in future (eg on the grounds of non-obviousness or existence of prior art) and/or that another technology may be employed to achieve a similar effect. The protracted development times mean the clock has been ticking on the original issued patents, reducing the protected commercial products




A smooth gel intended for alcohol soluble actives. Provides cooling effect upon application while leaving minimal residue




The cooling effect of a topically applied product can be evaluated using a validated handheld thermal imaging system. When the gel matrix is destroyed after application to the skin, the bound water and alcohol evaporates and a measurable cooling-effect results.

[broomrigg] 05/12/2022 09:52

50p by Xmas?

;-)

[lbo] 03/12/2022 11:48

Without medical diagnosis of the cause of the erectile dysfunction and of any potentially underlying serious medical conditions (such as CVD and diabetes), the risks associated with self-treatment of erectile dysfunction outweigh the benefits



Sildenafil and tadalafil are recommended firstline treatments for erectile dysfunction (ED). Sildenafil was legally reclassified to a pharmacy medicine in the UK in 2018.

The two-fold increase in the rate of primary care prescriptions in the past 10 years suggests that more men are being screened for, or seeking help for, ED. The higher rate of prescribing offers opportunity for monitoring of linked risk factors, such as diabetes mellitus, dyslipidaemia, and vascular disorders



Figures released by the British Association of Urological Surgeons show that 90 per cent of men with impotence have at least one underlying physical cause for their problem, with 40 per cent living with cardiovascular disease and 33 per cent with diabetes.

Cardiovascular disease is the leading cause of death globally, claiming an estimated 17.9 million lives each year according to the World Health Organisation.

[lbo] 03/12/2022 11:29

Yes it works ‘rather well’ based on not informing the user there is not even evidence of it working any better then another placebo arousal gel or even a cooling lubricant would work in a direct blind comparison study. As they all work on ‘belief’.

https//neo.life/2021/10/the-promise-of-pills-that-do-nothing/

‘you are the active ingredient’




For the few devices subject to a scientific review, the quality standards are flimsy. Randomized controlled trials, the gold standard, are infrequent. Most studies are unblinded, and thus prone to bias. The FDA settles for loosely defined reasonable assurance that a device is safe and effective, versus its higher standard of substantial evidence for drugs, which require studies with comparison groups that didnt receive the same treatment. Thus, data that would never be sufficient to support the approval of a drug can result in the approval of a device used to treat the same condition, potentially diverting patients from effective drugs to less-effective devices

[c140] 03/12/2022 09:45

Doesn't lbo's posts highlighting the placebo effect within ED options actually show that our product actually works rather well? Most are not interested in delving into the background information of a product as long as it does what it says on the tin. The HUT proves it works in the real world and is one reason I invested.

[petroc] 02/12/2022 18:54

A stock basher is someone who manipulates the market to cause a drop in asset prices.
Stock bashers disseminate misinformation in the hopes that investors will believe the false claims and sell their stock before the price drops.
These individuals often target low-priced companies that have little to no available information on the market and may have positions in assets whose prices fall.
Some bashers may act alone or in groups or they may work on behalf of other individuals.
Stock bashing is illegal and may be subject to fines and prosecution.

[petroc] 02/12/2022 18:50

Heheheheh! Losses' comment earlier didn't last long! He called LiarBO a person who is sparing with the truth and tends to 'give himself a helping hand', no doubt using all the unguents and gels at his disposal! Obviously LiarBO went crying to his mates and got the comment removed. LiarBO, don't think that getting Losses' comment removed means that we don't all think that about you anyway! I'm afraid the mods' powers don't extend to mind control! Bwahahahaha!

[lbo] 02/12/2022 18:49

https://www.asa.org.uk/rulings/pro-bono-bio-entrepreneur-ltd-a17-400871.htmlMed3000 was the placebo in FM57. Therefore Futura had initially believed Med3000 had no therapeutic effect. The FM57 study did not set out to measure the efficacy of Med3000. The ASA will therefore consider that its reported effectiveness by Futura was a 'post-hoc finding'. The CAP Code required that objective claims, including medical claims for a CE-marked medical device, be backed by evidencea certified Class IIb medical device. We understood that the device certification was granted by a body within the European Member States that had been designated to carry out conformity assessments under the Medical Device Directivehad been used as the placebo treatment in that study, and therefore the researcher had initially believed it had no therapeutic effect. The trial did not set out to measure the efficacyits reported effectiveness by the advertiser was a post-hoc finding due to the risk of that being a false positive findingWe were also concerned that there was not an adequate placebo control in the trial. We, therefore, considered that the study did not provide adequate evidence for the claim ˜clinically proven’https://www.nice.org.uk/advice/mib80One specialist commentator felt that the clinical effectiveness has not been demonstrated. The absence of an adequate placebo (an inactive topical gel) for highlighted as a limitation by 3 commentators. One commentator said that without it, the clinical effectiveness could be attributed to the placebo effect of rubbing a gel

[lbo] 02/12/2022 18:46

Because the trial was not placebo-controlled, we considered AcceleDent had not provided adequate evidence to support the claim ˜AcceleDent’ is also clinically proven to reduce the pain and discomfort associated with braces and aligners by up to 71%. We concluded that the claim had not been substantiated and was misleading.

On that point the claim breached CAP Code (Edition 12) rules 3.1 (Misleading advertising), 3.7 (Substantiation) and 12.1 Medicines, medical devices, health-related products and beauty products.




Assessment

Upheld

The ASA noted that the product appeared to meet the requirements of the Medical Device Directive (MDD) but understood that the MDD did not harmonise EU law relating the advertising of medical devices, which was subject to Directive 2005/29/EC on unfair business to consumer commercial practices (including advertising) generally (Unfair commercial practices directive - UCPD). That meant that advertisers must still meet the requirements of the CAP Code, which reflected the provisions of UCPD. Under the CAP and BCAP Codes, medical claims could be made for CE-marked medical devices provided they complied with other requirements of the Codes, including those relating to substantiation. We understood that the Aerosure Medic was classified as Class I medical device. Class I medical devices were generally CE-marked on a self-declaration basis. CE certification in itself does not constitute evidence for medical efficacy claims, and advertisers need to ensure that they hold evidence for such claims.

There was no statistically significant difference between the outcomes for the treatment group (patients using the Aerosure device) and the control group (using an inactive sham device). The study was accordingly not adequate evidence of the efficacy of the device.

[petroc] 02/12/2022 18:18

'A stock basher is someone who manipulates the market to cause a drop in asset prices.

Stock bashers disseminate misinformation in the hopes that investors will believe the false claims and sell their stock before the price drops.

These individuals often target low-priced companies that have little to no available information on the market and may have positions in assets whose prices fall.

Some bashers may act alone or in groups or they may work on behalf of other individuals.

Stock bashing is illegal and may be subject to fines and prosecution.'

I hope you took note of the last one there, LiarBO. I know very well how you always copy/paste your malicious quotes from other people, rather than say them yourself, covering your tracks for when the day comes that the FUM legal dept catches up with you. Unfortunately for you a court of law will still find you as guilty as if you said them yourself. So why not quit now, before the day inevitably comes when MED3000 hits the market and makes a great deal of money for us shareholders? (Which doesn't include you as you sold your holding for a massive loss 5 years ago)

[petroc] 02/12/2022 18:17

Losses, very astute of you. However, LiarBO runs crying to his mates, the moderators, when you call him names. Expect a little message in your inbox!